Literature DB >> 25428147

Discrimination between active and latent tuberculosis based on ratio of antigen-specific to mitogen-induced IP-10 production.

Yun Hee Jeong1, Yun-Gyoung Hur2, Hyejon Lee2, Sunghyun Kim3, Jang-Eun Cho4, Jun Chang5, Sung Jae Shin2, Hyeyoung Lee3, Young Ae Kang6, Sang-Nae Cho2, Sang-Jun Ha7.   

Abstract

Mycobacterium tuberculosis is the major causative agent of tuberculosis (TB). The gamma interferon (IFN-γ) release assay (IGRA) has been widely used to diagnose TB by testing cell-mediated immune responses but has no capacity for distinguishing between active TB and latent TB infection (LTBI). This study aims to identify a parameter that will help to discriminate active TB and LTBI. Whole-blood samples from 33 active TB patients, 20 individuals with LTBI, and 26 non-TB controls were applied to the commercial IFN-γ release assay, QuantiFERON-TB Gold In-Tube, and plasma samples were analyzed for interleukin-2 (IL-2), IL-6, IL-8, IL-10, IL-13, tumor necrosis factor-alpha (TNF-α), IFN-γ, monokine induced by IFN-γ (MIG), interferon gamma inducible protein 10 (IP-10), interferon-inducible T cell alpha chemoattractant (I-TAC), and monocyte chemoattractant protein 1 (MCP-1) by using a commercial cytometric bead array. The Mycobacterium tuberculosis antigen-specific production of most of the assayed cytokines and chemokines was higher in the active TB than in the LTBI group. The mitogen-induced responses were lower in the active TB than in the LTBI group. When the ratio of TB-specific to mitogen-induced responses was calculated, IL-2, IL-6, IL-10, IL-13, TNF-α, IFN-γ, MIG, and IP-10 were more useful in discriminating active TB from LTBI. In particular, most patients showed higher IP-10 production to Mycobacterium tuberculosis antigens than to mitogen at the individual level, and the ratio for IP-10 was the strongest indicator of active infection versus LTBI with 93.9% sensitivity and 90% specificity. In conclusion, the ratio of the TB-specific to the mitogen-induced IP-10 responses showed the most promising accuracy for discriminating active TB versus LTBI and should be further studied to determine whether it can serve as a biomarker that might help clinicians administer appropriate treatments.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25428147      PMCID: PMC4298513          DOI: 10.1128/JCM.02758-14

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  34 in total

Review 1.  Clinical practice. Latent tuberculosis infection.

Authors:  Robert M Jasmer; Payam Nahid; Philip C Hopewell
Journal:  N Engl J Med       Date:  2002-12-05       Impact factor: 91.245

2.  Sensitivity of a new commercial enzyme-linked immunospot assay (T SPOT-TB) for diagnosis of tuberculosis in clinical practice.

Authors:  T Meier; H-P Eulenbruch; P Wrighton-Smith; G Enders; T Regnath
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-08       Impact factor: 3.267

3.  WHO publishes Global tuberculosis report 2013.

Authors: 
Journal:  Euro Surveill       Date:  2013-10-24

4.  Novel tuberculosis vaccination strategies based on understanding the immune response.

Authors:  S H E Kaufmann
Journal:  J Intern Med       Date:  2010-04       Impact factor: 8.989

Review 5.  Understanding latent tuberculosis: a moving target.

Authors:  Philana Ling Lin; Joanne L Flynn
Journal:  J Immunol       Date:  2010-07-01       Impact factor: 5.422

6.  Raised plasma concentration and ex vivo production of inflammatory chemokines in patients with systemic lupus erythematosus.

Authors:  L C W Lit; C K Wong; L S Tam; E K M Li; C W K Lam
Journal:  Ann Rheum Dis       Date:  2005-06-23       Impact factor: 19.103

7.  Chemokine response in mice infected with Mycobacterium tuberculosis.

Authors:  E R Rhoades; A M Cooper; I M Orme
Journal:  Infect Immun       Date:  1995-10       Impact factor: 3.441

8.  CXCR3 chemokine receptor-plasma IP10 interaction in patients with coronary artery disease.

Authors:  Akira Kawamura; Shin-ichiro Miura; Masahiro Fujino; Hiroaki Nishikawa; Yoshino Matsuo; Hiroaki Tanigawa; Sayo Tomita; Yoshihiro Tsuchiya; Kunihiro Matsuo; Keijiro Saku
Journal:  Circ J       Date:  2003-10       Impact factor: 2.993

9.  Evaluating the potential of IP-10 and MCP-2 as biomarkers for the diagnosis of tuberculosis.

Authors:  M Ruhwald; T Bodmer; C Maier; M Jepsen; M B Haaland; J Eugen-Olsen; P Ravn
Journal:  Eur Respir J       Date:  2008-08-06       Impact factor: 16.671

10.  IP-10, MCP-1, MCP-2, MCP-3, and IL-1RA hold promise as biomarkers for infection with M. tuberculosis in a whole blood based T-cell assay.

Authors:  Morten Ruhwald; Morten Bjerregaard-Andersen; Paulo Rabna; Jesper Eugen-Olsen; Pernille Ravn
Journal:  BMC Res Notes       Date:  2009-02-04
View more
  20 in total

1.  Diagnostic Usefulness of Cytokine and Chemokine Levels in the Cerebrospinal Fluid of Patients with Suspected Tuberculous Meningitis.

Authors:  Ji-Soo Kwon; Joung Ha Park; Ji Yeun Kim; Hye Hee Cha; Min-Jae Kim; Yong Pil Chong; Sang-Oh Lee; Sang-Ho Choi; Yang Soo Kim; Jun Hee Woo; Yong Seo Koo; Sang-Beom Jeon; Sang-Ahm Lee; Sung-Han Kim
Journal:  Am J Trop Med Hyg       Date:  2019-08       Impact factor: 2.345

2.  [Plasma levels of interferon-inducible protein 10 in patients with active pulmonary tuberculosis with different affected areas].

Authors:  Haiping Dong; Zhihui Liu; Xiaocheng Liang; Yiluan Jian; Dexian Li; Suihua Lao; Feng Liang; Yanshan Pan; Xiaojia Kuang
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2019-05-30

Review 3.  Cytokines and Chemokines in Mycobacterium tuberculosis Infection.

Authors:  Racquel Domingo-Gonzalez; Oliver Prince; Andrea Cooper; Shabaana A Khader
Journal:  Microbiol Spectr       Date:  2016-10

Review 4.  Macrophage-microbe interaction: lessons learned from the pathogen Mycobacterium tuberculosis.

Authors:  Somdeb BoseDasgupta; Jean Pieters
Journal:  Semin Immunopathol       Date:  2018-10-10       Impact factor: 9.623

5.  Elevated Neopterin Levels Are Associated with Increased Tuberculosis Risk in Rheumatoid Arthritis Patients with QuantiFERON Conversion during Biologic Therapy.

Authors:  Der-Yuan Chen; Ju-Pi Li; Yi-Ming Chen; Tsai-Ling Liao; Hsin-Hua Chen; Chia-Wei Hsieh; Yea-Wen Yeh; Joung-Liang Lan
Journal:  PLoS One       Date:  2016-11-18       Impact factor: 3.240

6.  ORFeome-based identification of biomarkers for serodiagnosis of Mycobacterium tuberculosis latent infection.

Authors:  Fangbin Zhou; Xindong Xu; Sijia Wu; Xiaobing Cui; Weiqing Pan
Journal:  BMC Infect Dis       Date:  2017-12-28       Impact factor: 3.090

7.  Unique Chemokine Profiles of Lung Tissues Distinguish Post-chemotherapeutic Persistent and Chronic Tuberculosis in a Mouse Model.

Authors:  Soomin Park; Seung-Hun Baek; Sang-Nae Cho; Young-Saeng Jang; Ahreum Kim; In-Hong Choi
Journal:  Front Cell Infect Microbiol       Date:  2017-07-13       Impact factor: 5.293

8.  Analysis of aqueous humor concentrations of cytokines in retinoblastoma.

Authors:  Yong Cheng; Shufeng Zheng; Chung-Ting Pan; Mengke Yuan; Libin Chang; Yuou Yao; Mingwei Zhao; Jianhong Liang
Journal:  PLoS One       Date:  2017-05-09       Impact factor: 3.240

9.  Combined Analysis of IFN-γ, IL-2, IL-5, IL-10, IL-1RA and MCP-1 in QFT Supernatant Is Useful for Distinguishing Active Tuberculosis from Latent Infection.

Authors:  Maho Suzukawa; Shunsuke Akashi; Hideaki Nagai; Hiroyuki Nagase; Hiroyuki Nakamura; Hirotoshi Matsui; Akira Hebisawa; Ken Ohta
Journal:  PLoS One       Date:  2016-04-01       Impact factor: 3.240

10.  The Use of Interferon Gamma Inducible Protein 10 as a Potential Biomarker in the Diagnosis of Latent Tuberculosis Infection in Uganda.

Authors:  Irene Andia Biraro; Simon Kimuda; Moses Egesa; Stephen Cose; Emily L Webb; Moses Joloba; Steven G Smith; Alison M Elliott; Hazel M Dockrell; Achilles Katamba
Journal:  PLoS One       Date:  2016-01-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.